Reaction

Gastrointestinal Wall Thickening reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,466 reports · 41 co-occurring drugs

As of the last recalculation, Gastrointestinal Wall Thickening appears in 1,466 FAERS reports alongside 41 co-occurring drug terms. The strongest observed disproportionality signal is MERCAPTOPURINE (PRR 33.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Mercaptopurine	40	33.6	33.7
Cholestyramine	26	31.1	31.1
Pegaspargase	25	29.5	29.5
Vedolizumab	117	20.9	20.9
Adalimumab-Fkjp	63	20.1	20.2
Adalimumab-Aaty	63	19.7	19.7
Anti-Thymocyte Globulin (Rabbit)	10	17.7	17.7
Adalimumab-Adaz	63	17.7	17.7
Azathioprine	102	17.6	17.6
Teduglutide	15	16.0	16.0
Voriconazole Injection	24	15.9	16.0
Budesonide	63	15.8	15.8
Metronidazole	63	14.6	14.6
Melphalan	22	13.9	13.9
Mesalamine	52	13.6	13.6
Cladribine	9	13.4	13.4
Infliximab-Dyyb	27	13.3	13.4
Melphalan Hydrochloride	23	13.2	13.2
Metronidazole Topical	43	13.2	13.2
Diphenoxylate Hydrochloride And Atropine Sulfate	12	12.5	12.5
Dabrafenib	18	12.3	12.3
Octreotide Acetate	26	12.3	12.3
Voriconazole	24	11.4	11.4
Tranexamic Acid	7	11.2	11.2
Piperacillin And Tazobactam	10	11.2	11.2
Irinotecan Hydrochloride	10	11.1	11.1
Risankizumab-Rzaa	61	11.0	11.0
Trametinib	18	10.7	10.7
Cytarabine	44	10.7	10.7
Upadacitinib	57	10.3	10.3
Adalimumab	380	9.9	9.9
Leucovorin Calcium	13	9.7	9.7
Vincristine Sulfate	18	8.8	8.8
Niraparib	13	8.4	8.4
Ustekinumab	58	8.3	8.3
Dapagliflozin	15	6.8	6.8
Fluticasone Furoate And Vilanterol Trifenatate	17	6.8	6.8
Doxorubicin Hydrochloride	15	6.6	6.6
Remdesivir	6	6.4	6.4
Encorafenib	4	5.7	5.8
Eltrombopag Olamine	7	4.3	4.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.